hainan huluwa pharmaceutical group announced that its stock has experienced abnormal trading fluctuations and issued a risk warning, stating that the company's stock has hit the daily trading limit for 7 consecutive trading days from November 26, 2024, to December 4, 2024, with a cumulative increase of 94.89%. The turnover ratio over the last 7 trading days was 29.65%, and the stock price has increased significantly compared to the sse composite index and the average level of the pharmaceutical manufacturing industry during the same period, which may indicate irrational speculation. The company's pe and pb are higher than the industry average. As of December 3, 2024, the company's static pe was 85.92, rolling pe was 81.06, and pb was 7.93; while the average static pe for the pharmaceutical manufacturing industry was 28.10, rolling pe was 27.92, and pb was 2.74. After a self-examination and verification, the company confirms that there are no significant matters that should be disclosed but have not been disclosed, production and operation activities are normal, and there have been no significant adjustments in the market environment or industry policy. Production costs and sales conditions have not experienced significant fluctuations, internal production and operation order is normal, and there have been no significant changes in the main business.